Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

    ... haemoglobinuria (PNH) in patients with resistance to eculizumab due to complement C5 polymorphisms ...

    Clinical Trial last updated 08/26/2016 - 11:59am.

  2. Biology Teacher Battles PNH

    ... in 2015, he is  grateful that he has responded well to eculizumab (Soliris®) treatment. “I’m incredibly fortunate,” he ... by the language and the pictures and the charts.” Eculizumab has worked well enough for Steve, but he is eager to stay on top of ...

    Patient Chronicle last updated 06/28/2016 - 8:15am.

  3. A Rare Genetic Polymorphism in C5 Confers Poor Response to the Anti-C5 Monoclonal Antibody Eculizumab by Nine Japanese Patients with PNH

    ... who seem to have absolutely no benefit at all from eculizumab . Eculizumab binds to and inactivates the C5 complement protein and protects the ...

    Research Review last updated 05/02/2016 - 9:25am.

  4. Improved Fatigue and Quality-of-Life in Patients with Paroxysmal Nocturnal Hemoglobinuria During Treatment with Eculizumab: Data from the Global PNH Registry

    ... PNH have a major impact on patients’ quality of life. Eculizumab (Soliris®) can prevent hemolysis in people with PNH. The ... age 41) in the PNH Registry who had been treated with eculizumab for 12 months. The patients completed questionnaires to assess their ...

    Research Review last updated 05/02/2016 - 9:21am.

  5. Self-injected PNH therapy on the horizon

    ... (PNH), behind intravenous (I.V.) Soliris ( eculizumab , Alexion Pharmaceuticals Inc.), given every other week. Coversin ...

    Article last updated 07/07/2016 - 9:40am.

  6. Pregnancy in Bone Marrow Failure Disease

    ... ability to become pregnant. For PNH, has the use of eculizumab in pregnancy been studied? There are cases of women who have been successfully treated with eculizumab. Recent information shows that with modern obstetric care, women ...

    Interview last updated 01/13/2017 - 9:28am.

  7. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria

    ... blockade through the anti-C5 monoclonal antibody eculizumab . This brief review focuses on two specific aspects of PNH: (1) response to eculizumab, variability of response, and how this new agent has impacted ...

    Research Article last updated 06/07/2016 - 10:56am.

  8. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients

    ... complement regulators. Blockage of the lytic pathway by eculizumab is the only available therapy for PNH patients and shows ... to untargeted inhibition of all complement pathways by eculizumab. Thus, the molecular design of each C3-opsonin targeted complement ...

    Research Article last updated 04/29/2016 - 12:58pm.

  9. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

    ... resulting in erythrocyte lysis. The availability of eculizumab as the first complement inhibitor for clinical use renewed the ... independence in at least half of PNH patients receiving eculizumab, with adequate control of all hemolysis-associated symptoms even in ...

    Research Article last updated 05/22/2014 - 8:24am.

  10. Complement Blockade with a C1 Esterase Inhibitor in Paroxysmal Nocturnal Hemoglobinuria

    ... context of underlying complement activation. Currently eculizumab effectively blocks the intravascular hemolysis PNH. There ... products on CD55 deficient erythrocytes from PNH patient on eculizumab therapy. This could suggest a role for inhibition of earlier phases ...

    Research Article last updated 08/04/2014 - 8:13am.